![\"\"](\"http:\/\/event.roseliassociates.com\/novel-approaches-to-preventing-publication-bias\/wp-content\/uploads\/sites\/81\/2023\/12\/Chesi.png\")
<\/p>\n<\/p>\n
Marta Chesi is an Associate Professor of Medicine at Mayo Clinic Arizona. Over the course of three decades, in collaboration with Dr. Bergsagel, she has identified most of the primary and secondary genomic events that contribute to the molecular pathogenesis of multiple myeloma and constitute the basis for disease stratification worldwide. The immunocompetent Vk*MYC transgenic mouse model she has generated has allowed to demonstrate in vivo<\/em> the functional consequences of some of those genomic aberrations in the context of a proper tumor microenvironment and, in collaboration with industry, to identify clinically relevant therapeutic approaches to target them. More recently, she has been focusing on the preclinical development of immunotherapy in a fully immunocompetent, orthotopic and clinically relevant setting, studying the interaction of T-cells redirecting therapies (bispecific antibodies and CAR-T cells) with conventional therapies of myeloma.<\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" Marta Chesi is an Associate Professor of Medicine at Mayo Clinic Arizona. Over the course of three decades, in collaboration with Dr. Bergsagel, she has identified most of the primary and secondary genomic events that contribute to the molecular pathogenesis of multiple myeloma and constitute the basis for disease stratification worldwide. The immunocompetent Vk*MYC transgenic<\/p>\n","protected":false},"author":6,"featured_media":5463,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":["post-5462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-creative"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t